Deferred Tax Assets, Valuation Allowance of Corvus Pharmaceuticals, Inc. from 31 Dec 2015 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Corvus Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2015 to 31 Dec 2025.
  • Corvus Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $102,099,000, a 13% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Corvus Pharmaceuticals, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $102,099,000 +$11,566,000 +13% 31 Dec 2025 10-K 12 Mar 2026 2025 FY
Q4 2024 $90,533,000 +$7,555,000 +9.1% 31 Dec 2024 10-K 12 Mar 2026 2025 FY
Q4 2023 $82,978,000 +$6,647,000 +8.7% 31 Dec 2023 10-K 25 Mar 2025 2024 FY
Q4 2022 $76,331,000 +$9,203,000 +14% 31 Dec 2022 10-K 25 Mar 2025 2024 FY
Q4 2021 $67,128,000 +$11,446,000 +21% 31 Dec 2021 10-K 19 Mar 2024 2023 FY
Q4 2020 $55,682,000 +$1,459,000 +2.7% 31 Dec 2020 10-K 28 Mar 2023 2021 FY
Q4 2019 $54,223,000 +$12,986,000 +31% 31 Dec 2019 10-K 10 Mar 2022 2021 FY
Q4 2018 $41,237,000 +$19,352,000 +88% 31 Dec 2018 10-K 25 Mar 2021 2020 FY
Q4 2017 $21,885,000 +$9,094,000 +71% 31 Dec 2017 10-K 09 Mar 2020 2019 FY
Q4 2016 $12,791,000 +$6,925,000 +118% 31 Dec 2016 10-K 07 Mar 2019 2018 FY
Q4 2015 $5,866,000 31 Dec 2015 10-K 01 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.